Recently, a research team has developed a method for treating AD using mesenchymal stem cell-derived extracellular vesicles (MSC-EVs-SHP2) with high expression of tyrosine phosphatase-2 (SHP2). The gene discussed is PTPN11; the disease is Alzheimer disease.